n-chief of Geriatrics, a journal for primary care physicians, for 14 years and has authored approximately 300 scientific and medical articles. Dr. Butler won the Pulitzer Prize for his book Why Survive? Being Old in America. His latest book is The Longevity Revolution.
ALAMEDA, Calif. (Business Wire EON) August 6, 2008 -- "The aging of the baby boom generation is the most significant demographic trend of our time," said Michael D. West, Ph.D., BioTime's Chief Executive Officer. "We look forward in working with Dr. Butler in focusing the emerging technologies of regenerative medicine on the large and growing markets in age-related degenerative disease."
- Butler said, "It is exciting to be elected to the board of BioTime, an innovative company built for this era of longevity."
About BioTime, Inc. (BTIM.OB):
BioTime, headquartered in Alameda, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Additional information about BioTime can be found on the web at www.biotimeinc.com. Hextend, PentaLyte, HetaCool, EmbryomicsTM, ESpyTM, and ESpanTM are trademarks of BioTime, Inc.
Forward-Looking Statements
'/>"/>
Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry2.
Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts3.
Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors4.
Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar5.
Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics6.
Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer7.
Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer8.
WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer9.
Hiemstra Appoints Robert C. Glines as Director of Business Development10.
Elusys Therapeutics Appoints Robert Gundel as Vice President of Research11.
Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems